Tag: Johnson & Johnson

A surge in institutional buying activity is placing a traditional healthcare conglomerate firmly on the radar of major market players. ...

Johnson & Johnson is currently bolstering its healthcare portfolio with significant operational progress. The company has achieved a key regulatory ...

Facing the impending loss of patent protection for its blockbuster drug Stelara in 2025, Johnson & Johnson has been under ...

Facing the impending loss of patent protection for its key immunology drug Stelara, Johnson & Johnson is strategically bolstering its ...

Johnson & Johnson has secured a pivotal victory in the treatment of blood cancer, marking a significant advancement for both ...

Despite securing two significant regulatory approvals from the U.S. Food and Drug Administration (FDA) in early March 2026, shares of ...

The healthcare giant Johnson & Johnson is pursuing a dual strategy to enhance patient access and advance its pipeline. In ...

Investor confidence in Johnson & Johnson is strengthening, fueled by a significant regulatory milestone that adds momentum to the stock's ...

Johnson & Johnson shares are trading near record highs, yet major institutional investors are sending mixed signals through their recent ...

A California jury has delivered a significant legal blow to Johnson & Johnson, ordering the healthcare giant to pay $40 ...